Sociedad Americana de Hirudoterapia

Thrombosis and Coagulopathy

Review published in Neurosurgery clinics of North America (2025)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Systematic reviewEnsayos clínicosFarmacología salivalSavi M et al. · Neurosurgery clinics of North America, 2025

Abstract

Effective anticoagulation management is crucial for balancing thromboembolism and hemorrhage risks in patients with traumatic brain injury (TBI) and spinal cord injury (SCI). A systematic review from January 1984 to August 2024 highlights a growing preference for prothrombin complex concentrate (PCC) as the primary reversal agent, with limited evidence on idarucizumab for dabigatran. Most studies show that 4F-PCC improves mortality and hemostatic efficacy, facilitating faster surgical interventions. The lack of large clinical trials remains a significant gap, limiting the development of standardized protocols. Increasing use of viscoelastic assays for assessing residual anticoagulant activity offers potential for more personalized treatment strategies.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleSystematic Review
Indexed MeSH termsHumansBlood Coagulation DisordersThrombosisBrain Injuries, TraumaticAnticoagulantsSpinal Cord InjuriesBlood Coagulation Factors

Resumen

Effective anticoagulation management is crucial for balancing thromboembolism and hemorrhage risks in patients with traumatic brain injury (TBI) and spinal cord injury (SCI).

Por qué esto importa para la hirudoterapia

This systematic review (January 1984–August 2024) examined anticoagulation management in traumatic brain injury and spinal cord injury, finding a growing preference for 4F-prothrombin complex concentrate as the primary reversal agent, limited evidence on idarucizumab for dabigatran, and increasing use of viscoelastic assays for assessing residual anticoagulant activity. The abstract does not mention leeches, hirudotherapy, hirudin, or any leech-derived compounds at any point. The review's focus is entirely on pharmacological anticoagulation reversal strategies in trauma patients, and there is no defensible connection to ASH's domain of hirudotherapy or the leech secretome based on this abstract.

Citación

Thrombosis and Coagulopathy

Savi M et al. · Neurosurgery clinics of North America, 2025

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.